Cipargamin(KAE609)治疗成人无并发症恶性疟的II期剂量递增研究
该II期多中心随机开放标签剂量递增试验在撒哈拉以南非洲成人无并发症恶性疟患者中评估Cipargamin单药疗效。单次≥50 mg或每日50 mg连用3天的各剂量均快速清除疟原虫,中位原虫清除时间8小时,14天和28天PCR校正ACPR分别>75%和65%;65%治疗失败者检出Pfatp4 G358S突变。
要点
- ≥50 mg各剂量中位原虫清除时间8小时,快于蒿甲醚-苯芴醇的24小时。
- 各剂量14天PCR校正ACPR>75%,28天>65%。
- 65%治疗失败者检出治疗中出现的Pfatp4 G358S突变。
核心结论
- Cipargamin单次50至150 mg可非常快速清除疟原虫,成人无并发症恶性疟28天PCR校正ACPR>65%,复发虫株常携带治疗中出现的突变,后续将与合适联合伙伴开发。
研究设计与样本
- II期多中心随机开放标签剂量递增试验,在撒哈拉以南非洲成人无并发症恶性疟患者中开展,Cipargamin单药单次至150 mg或50 mg每日一次连用3天,以蒿甲醚-苯芴醇为对照;本文报告疗效、药代动力学和耐药标志物等次要终点。
主要发现
- 所有单次或多剂Cipargamin≥50 mg均快速清除疟原虫,中位PCT为8小时,蒿甲醚-苯芴醇为24小时。
- 各Cipargamin剂量14天PCR校正ACPR>75%,28天>65%。
- 65%的治疗失败者检出Pfatp4基因G358S治疗中出现的突变。
- 药代动力学参数与既往数据一致,大致呈剂量比例关系。
临床怎么用
- Cipargamin单药可快速清除原虫但28天PCR校正ACPR有限,且复发常伴Pfatp4 G358S突变,提示不宜单药使用,需与合适联合伙伴进一步开发。
局限性
- 本文报告的是次要终点,研究主要目的为评估肝脏安全性(肝脏安全性数据另文报告)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cipargamin (KAE609) is a potent antimalarial in a phase II trial. Here we report efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin doses. These were secondary endpoints from a study primarily conducted to assess the hepatic safety of cipargamin (hepatic safety data are reported elsewhere). METHODS: This phase II, multicenter, randomized, open-label, dose-escalation trial was conducted in sub-Saharan Africa in adults with uncomplicated Plasmodium falciparum malaria. Cipargamin monotherapy was given as single doses up to 150 mg or up to 50 mg once daily for 3 days, with artemether-lumefantrine as control. Key efficacy endpoints were parasite clearance time (PCT), and polymerase chain reaction (PCR)-corrected and uncorrected adequate clinical and parasitological response (ACPR) at 14 and 28 days. Pharmacokinetics and molecular markers of drug resistance were also assessed. RESULTS: All single or multiple cipargamin doses ≥50 mg were associated with rapid parasite clearance, with median PCT of 8 hours versus 24 hours for artemether-lumefantrine. PCR-corrected ACPR at 14 and 28 days was >75% and 65%, respectively, for each cipargamin dose. A treatment-emerging mutation in the Pfatp4 gene, G358S, was detected in 65% of treatment failures. Pharmacokinetic parameters were consistent with previous data, and approximately dose proportional. CONCLUSIONS: Cipargamin, at single doses of 50 to 150 mg, was associated with very rapid parasite clearance, PCR-corrected ACPR at 28 days of >65% in adults with uncomplicated P. falciparum malaria, and recrudescent parasites frequently harbored a treatment-emerging mutation. Cipargamin will be further developed with a suitable combination partner. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov (NCT03334747).
引用
- Schmitt EK, Ndayisaba G, Yeka A, et al. Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria. Clin Infect Dis. 2022. PMID: 34410358. doi:10.1093/cid/ciab716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。